General
Preferred name
TILUDRONIC ACID
Synonyms
Tiludronate (disodium) ()
TILUDRONATE DISODIUM ()
Tiludronic acid (disodium) ()
Tiludronic acid disodium salt ()
tiludronate ()
SR-41319 ()
SR 41319 ()
Skelid ()
SR-41319B ()
Tiludronate disodium anhydrous ()
Tiludronate sodium ()
SR 41319B ()
P&D ID
PD009787
CAS
89987-06-4
149845-07-8
Tags
available
drug
Approved by
FDA
First approval
1997
Drug Status
investigational
approved
vet_approved
Max Phase
Phase 4
Drug indication
Paget's Disease Treatment
Osteoporosis Treatment And Prevention
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tiludronic acid belongs to the same non-nitrogenous bisphosphonate drug family as and clodronic acid (PubChem CID 25419). Marketed formulations contain tiludronate disodium (PubChem CID 60936).
(GtoPdb)
DESCRIPTION
The disodium salt form of Tiludronic acid which has been found to be a biphosphonate bone resorption inhibitor and could be used against osteitis deformans.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
52
Molecular Weight
317.93
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
2.07
TPSA
115.06
Fraction CSP3
0.14
Chiral centers
0.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
navicular syndrome
Target
ATP6V1A, MMP2, PTPN1
Proton Pump
MOA
bone resorption inhibitor, osteoclast inhibitor
Pathway
Membrane Transporter/Ion Channel
Source data
